NCT02454478 2019-03-19
Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)
Eisai Inc.
Phase 1 Completed
Eisai Inc.
Novartis
University of Chicago
Novartis
Novartis
Novartis
Novartis
Novartis